Compare SINT & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SINT | BOLT |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1M | 10.5M |
| IPO Year | 2007 | 2021 |
| Metric | SINT | BOLT |
|---|---|---|
| Price | $2.35 | $5.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $11.00 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 39.0K | 20.7K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.45 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,018,000.00 | ★ $7,695,000.00 |
| Revenue This Year | $30.26 | N/A |
| Revenue Next Year | $413.20 | $133.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 0.07 |
| 52 Week Low | $1.99 | $0.26 |
| 52 Week High | $6.78 | $7.35 |
| Indicator | SINT | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 45.43 | 58.59 |
| Support Level | $2.28 | $4.32 |
| Resistance Level | $2.98 | $5.67 |
| Average True Range (ATR) | 0.15 | 0.35 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 38.49 | 81.35 |
SINTX Technologies Inc is an advance ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. It provides biomedical solutions for medical devices specializing in silicon nitride (Si3N4) for musculoskeletal and antipathogenic applications. It also manufactures silicon nitride parts for customers in the electrical, aerospace, and other industrial sectors. The company is a globalised leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans. The Company operates as one operating segment.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.